New atlas maps potential of genes to predict adverse drug reactions, per comprehensive study of Million Veteran Program and other genetic data.
Article URL: https://plos.io/4hcj8Jd
Article Title: A genomic-led strategy to anticipate drug safety effects
Author Countries: Italy, United Kingdom, United States
Funding: This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #MVP000 (KC, MG, GW, DG, BF, AP, KGP, RM, LC, NK). This publication does not represent the views of the Department of Veteran Affairs or the United States Government. This research used resources from the Knowledge Discovery Infrastructure at the Oak Ridge National Laboratory, supported by the Office of Science of the U.S. Department of Energy under Contract No. DE-AC05-00OR22725 (KC, MG, GW, DG, BF, AP, KGP, RM, LC, NK) and the Department of Veterans Affairs Office of Information Technology Inter-Agency Agreement with the Department of Energy under IAA No. VA118-16-M-1062. JCW is funded by the UK Medical Research Council via programme grant MC_UU_00002/18. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PLOS Genetics
16-Jul-2026
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Maya Ghoussaini is a full-time employee at Regeneron Genetics Centre. Maya’s main contributions were while she was an employee of Open Targets. Mohd Karim is a full-time employee at Variant Bio. Mohd’s main contributions were while he was a an employee of Open Targets. JP Casas is a full-time employee at Novartis Institutes for Biomedical Research. JP Casas’ main contributions to the project were while employed at the VA Boston Healthcare System.